health
March 2, 2026
Why Novo Nordisk's Ireland expansion is key to fighting off Eli Lilly
Novo Nordisk is investing in a facility in Ireland as it expands its production capacities of the newly launched Wegovy pill, the Danish drugmaker said Monday.
TL;DR
- Novo Nordisk is investing 432 million euros in an Irish facility to expand production of the Wegovy pill.
- The investment aims to meet both current and future demand for oral products outside the U.S.
- This expansion follows a strong U.S. launch of the Wegovy pill and precedes its review by the European Medicines Agency.
- The company has previously faced supply issues with its GLP-1 drugs but claims these have been resolved.
- Analysts see the investment as a sign of Novo Nordisk's focus on oral drug development and a strategy to counter Eli Lilly's market entry.
- The construction in Ireland will be completed gradually through 2027 and 2028, and may focus on experimental oral drugs.
Continue reading the original article